Work

Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis

Year: 2011

Type: article

Abstract: Methods Patients with polyarticular course JIA (N=171) were enrolled in a phase 3, randomized-withdrawal, doubleblind (DB), stratified, parallel-group study, which consisted of a 16-wk open-label (OL) lead-in, a 32-wk DB phase, and an up to 5 year OL extension phase that included BSA dosing prior to a switch to fixed dose (FD). Patients on ADA (24 mg/m; max dose, 40 mg) were evaluated based on ACR pediatric response criteria for improvement (ACR Pedi 30/50/70/90) and monitored for adverse events (AEs).

Source: Pediatric Rheumatology

DOI: 10.1186/1546-0096-9-s1-o26